Theranostics Health signs collaboration agreement with Duke University

This relationship will provide Duke investigators access to the company’s core technologies, Laser Capture Microdissection and Reverse phase Protein Microarray. The proprietary combination of these technologies provides a powerful mechanism to accurately and reliably measure the aberrant protein signaling and protein molecular networks used by tumor cells obtained directly from a patients’ biopsy.

Emanuel Petricoin, chief scientific officer of Theranostics Health, said: “The future of cancer treatment is personalized, targeted therapies and patient stratification for clinical trials. We believe that this research collaboration with Duke will provide an important next step for our company in both research applications at the bench as well as working together with Duke investigators during Phase I, II and III clinical trials.”